Lungscape: Resected non-small-cell lung cancer outcome by clinical and pathological parameters

Journal of Thoracic Oncology

Volumn 9, Issue 11, 2014, Pages 1675-1684

  Peters, Solange ^a   Weder, Walter ^b   Dafni, Urania ^c   Kerr, Keith M ^d   Bubendorf, Lukas ^e   Meldgaard, Peter ^f   O'Byrne, Kenneth J ^g   Wrona, Anna ^h   Vansteenkiste, Johan ⁱ   Felip, Enriqueta ^j   Marchetti, Antonio ^k   Savic, Spasenija ^e   Lu, Shun ^l   Smit, Egbert ^m   Dingemans, Anne Marie ⁿ   Blackhall, Fiona H ^o   Baas, Paul ^p   Camps, Carlos ^q   Rosell, Rafael ^r   Stahel, Rolf A ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ATHENS   (Greece)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g ST JAMES S HOSPITAL   (Ireland)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k UNIVERSITY OF CHIETI   (Italy)

^l SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^m VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p NETHERLANDS CANCER INSTITUTE   (Netherlands)

^q UNIVERSITY OF VALENCIA   (Spain)

^r HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

NSCLC; Outcome; Patients' and pathological characteristics; Surgery; TNM stage

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; RADICAL RESECTION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; THORACOSCOPY; THORACOTOMY; TISSUE MICROARRAY; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925778718     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000320     Document Type: Article

References (26)

1. Group NM-aC, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-1277.
2. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
3. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-180.
4. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012;18:2443-2451.
5. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
6. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
7. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
8. Pignon JP, Tribodet H, Scagliotti GV, et al.; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
9. Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008;72:695-701.
10. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006.
11. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al.; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi89-vi98.
12. Bennouna J, Senellart H, Hiret S, Vaissiere N, Douillard JY. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer 2011;74:30-34.
13. th Edition. J Thorac Oncol 2008;3:457-466.
14. Koo HK, Jin SM, Lee CH, et al. Factors associated with recurrence in patients with curatively resected stage I-II lung cancer. Lung Cancer 2011;73:222-229.
15. Hung JJ, Jeng WJ, Hsu WH, Huang BS, Wu YC. Time trends of overall survival and survival after recurrence in completely resected stage I nonsmall cell lung cancer. J Thorac Oncol 2012;7:397-405.
16. Mountain CF, Lukeman JM, Hammar SP, et al. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol 1987;35:147-156.
17. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006;106:2428-2436.
18. Wu YC, Lin CF, Hsu WH, Huang BS, Huang MH, Wang LS. Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control. Eur J Cardiothorac Surg 2003;24:994-1001.
19. Poullis M, McShane J, Shaw M, et al. Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. Eur J Cardiothorac Surg 2013;43:919-924.
20. Park SY, Lee JG, Kim J, et al. The influence of smoking intensity on the clinicopathologic features and survival of patients with surgically treated non-small cell lung cancer. Lung Cancer 2013;81:480-486.
21. Alexiou C, Beggs D, Onyeaka P, et al. Pneumonectomy for stage I (T1N0 and T2N0) nonsmall cell lung cancer has potent, adverse impact on survival. Ann Thorac Surg 2003;76:1023-1028.
22. Alexiou C, Onyeaka CV, Beggs D, et al. Do women live longer following lung resection for carcinoma? Eur J Cardiothorac Surg 2002;21:319-325.
23. Fernandes OJ, Almgren SO, Thaning L, et al. Prognostic factors for the survival of surgically treated patients for non-small cell lung cancer. Acta Oncol 2003;42:338-341.
24. Iizasa T, Suzuki M, Yasufuku K, et al. Preoperative pulmonary function as a prognostic factor for stage I non-small cell lung carcinoma. Ann Thorac Surg 2004;77:1896-1902; discussion 1902.
25. Wang BY, Huang JY, Cheng CY, Lin CH, Ko J, Liaw YP. Lung cancer and prognosis in Taiwan: a population-based cancer registry. J Thorac Oncol 2013;8:1128-1135.
26. Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive stage I to III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project. J Clin Oncol 2014 Jul 28. pii:JCO2013.54.5921 [Epub ahead of print].